TrialJournal of cancer research and clinical oncology2020

Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109).

A Kurreck et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.